The post-hoc analyses of the phase III, randomized, multicenter, Iressa Pan-ASia Study (IPASS) study of 261 Asian patients (non-smokers) with EGFR mutation-positive advanced NSCLC were randomly assigned to receive gefitinib (250 mg/day) versus carboplatin/paclitaxel [34]. Here, EGFR is linked to non-small cell lung carcinoma.